George Massaro Sells 371 Shares of Charles River Laboratories International, Inc. (NYSE:CRL) Stock

Charles River Laboratories International, Inc. (NYSE:CRL) Director George Massaro sold 371 shares of the company’s stock in a transaction on Tuesday, May 11th. The shares were sold at an average price of $320.06, for a total value of $118,742.26. Following the completion of the sale, the director now owns 5,696 shares in the company, valued at $1,823,061.76. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

George Massaro also recently made the following trade(s):

  • On Thursday, May 6th, George Massaro sold 3,370 shares of Charles River Laboratories International stock. The shares were sold at an average price of $336.96, for a total value of $1,135,555.20.

NYSE:CRL traded down $3.74 during trading hours on Wednesday, reaching $316.76. The company’s stock had a trading volume of 740,737 shares, compared to its average volume of 341,908. The company has a market cap of $15.92 billion, a price-to-earnings ratio of 53.56, a price-to-earnings-growth ratio of 2.19 and a beta of 1.12. Charles River Laboratories International, Inc. has a one year low of $157.39 and a one year high of $349.13. The business’s 50-day moving average is $314.32 and its 200-day moving average is $273.06. The company has a debt-to-equity ratio of 1.04, a current ratio of 1.45 and a quick ratio of 1.22.

Charles River Laboratories International (NYSE:CRL) last issued its quarterly earnings data on Monday, May 3rd. The medical research company reported $2.53 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $2.19 by $0.34. The firm had revenue of $824.60 million during the quarter, compared to analysts’ expectations of $798.52 million. Charles River Laboratories International had a net margin of 10.68% and a return on equity of 22.41%. Charles River Laboratories International’s revenue for the quarter was up 16.6% on a year-over-year basis. During the same period in the prior year, the company posted $1.84 earnings per share. On average, sell-side analysts predict that Charles River Laboratories International, Inc. will post 7.87 EPS for the current fiscal year.

Hedge funds have recently added to or reduced their stakes in the business. Harbor Investment Advisory LLC bought a new stake in Charles River Laboratories International during the first quarter valued at about $29,000. Valeo Financial Advisors LLC bought a new stake in Charles River Laboratories International during the first quarter valued at about $35,000. Huntington National Bank boosted its holdings in Charles River Laboratories International by 121.8% during the first quarter. Huntington National Bank now owns 122 shares of the medical research company’s stock valued at $35,000 after acquiring an additional 67 shares during the period. Wealthcare Advisory Partners LLC bought a new stake in Charles River Laboratories International during the first quarter valued at about $35,000. Finally, Berman Capital Advisors LLC boosted its holdings in Charles River Laboratories International by 42.6% during the fourth quarter. Berman Capital Advisors LLC now owns 144 shares of the medical research company’s stock valued at $34,000 after acquiring an additional 43 shares during the period. Institutional investors own 92.30% of the company’s stock.

CRL has been the subject of several research reports. Zacks Investment Research lowered shares of Charles River Laboratories International from a “buy” rating to a “hold” rating in a research report on Monday, April 19th. Credit Suisse Group upped their price objective on shares of Charles River Laboratories International from $259.00 to $301.00 and gave the company a “neutral” rating in a research note on Thursday, February 18th. Morgan Stanley lifted their target price on shares of Charles River Laboratories International from $280.00 to $350.00 and gave the company an “overweight” rating in a research note on Thursday, February 25th. Robert W. Baird upped their price target on shares of Charles River Laboratories International from $338.00 to $400.00 and gave the stock an “outperform” rating in a research note on Wednesday, May 5th. Finally, Deutsche Bank Aktiengesellschaft upped their price target on shares of Charles River Laboratories International from $334.00 to $354.00 and gave the stock a “buy” rating in a research note on Wednesday, May 5th. Four investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $291.00.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc, an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing).

Read More: Net Income

Insider Buying and Selling by Quarter for Charles River Laboratories International (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International and related companies with MarketBeat.com's FREE daily email newsletter.